2018 Update of the EULAR recommendations for the management of large vessel vasculitis

Bernhard Hellmich,1 Ana Agueda,2 Sara Monti,3 Frank Buttgereit,4 Hubert de Boysson,5 Elisabeth Brouwer,6 Rebecca Cassie,7 Maria C Cid,8 Bhaskar Dasgupta,9 Christian Dejaco,10,11 Gulen Hatemi,12 Nicole Hollinger,13 Alfred Mahr,14 Susan P Mollan,15,16 Chetan Mukhtyar,17 Cristina Ponte,18,19 Carlo Salvarani,20 Rajappa Sivakumar,21 Xinping Tian,22 Gunnar Tomasson,23 Carl Turesson,24 Wolfgang Schmidt,25 Peter M Villiger,26 Richard Watts,27 Chris Young,28 Raashid Ahmed Luqmani29

Handling editor Josef S Smolen

► Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/annrheumdis-2019-215672).

For numbered affiliations see end of article.

Correspondence to Prof Dr Bernhard Hellmich, Klinik für Innere Medizin, Rheumatologie und Immunologie, Medius Kliniken, Eberhard Karls Universität Tübingen, 72076 Kirchheim-Teck, Germany; b.hellmich@medius-kliniken.de

Received 6 May 2019
Revised 10 June 2019
Accepted 10 June 2019
Published Online First 3 July 2019

ABSTRACT

Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations.

Methods Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations.

Results Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40–60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons.

Conclusions We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.

BACKGROUND

Rapid diagnosis and effective treatment are required in large vessel vasculitis (LVV) in order to treat symptoms, but more importantly, to reduce the risk of complications such as blindness in giant cell arteritis (GCA) and aortic aneurysm or vascular stenosis in GCA and Takayasu arteritis (TAK). In April 2008, the first recommendations of the European League against Rheumatism (EULAR) for managing LVV were published.1 These recommendations have provided guidance to clinicians and researchers and have been widely cited. Since then, the results of several randomised clinical trials and cohort analyses have become available and the EULAR recommendations on imaging in LVV have been published recently.2

In light of these and other fundamental developments affecting key areas of management, the goal of the current project was to re-evaluate the literature in order to update the EULAR recommendations for the management of LVV.

METHODS

The recommendations were drafted according to the 2014 update of the EULAR standardised operating procedures (SOPs) for the development of EULAR-endorsed recommendations and the updated version of the Appraisal of Guidelines for Research & Evaluation (AGREE II) recommendations, where applicable (see online supplementary file 1 for a full description of methods).3,4 The task force consisted of 20 clinical experts (including rheumatologists, internists, immunologists, a neurologist, a neuro-ophtalmologist and an epidemiologist), from 11 European countries, India and China, two fellows (AA, SM), one health professional and two patients affected by the diseases under study.

Based on results of a Delphi survey among the task force, we defined eight key research questions addressing the management and treatment of LVV. As the original systematic literature review (SLR) for the 2008 recommendations dated back 10 years ago with different methodology, it was decided to conduct two completely new SLRs without time limits, focusing on general management and treatment, respectively (table 1).

The following databases were used: MEDLINE, EMBASE and Cochrane CENTRAL. Each article was assigned a level of evidence (LoE) according to the standards of the Oxford Centre for Evidence-Based Medicine and was systematically assessed for bias. The methods and results of the two SLRs are published separately.5,6 During a face-to-face meeting, task force members independently voted on each recommendation.

Agreement on each recommendation and on the overarching principles on a scale of 0–10 (10 meaning full agreement) was given anonymously after the meeting by e-mail. A research agenda was formulated based on controversial issues and gaps in the evidence. The final manuscript was approved by the EULAR Executive Committee.

RESULTS
General aspects
The objective of the updated recommendations is to give advice on the management of LVV to rheumatologists and other health professions involved in the care of these patients. Because EULAR recommendations on imaging in LVV have been published recently, the task force agreed to refer to these recommendations removing topics regarding imaging from the update of the management recommendations.

To reduce confusion currently existing in the literature we propose new consensus definitions for disease activity states in LVV (table 2), based on the concept of activity states developed for the EULAR recommendations for small vessel vasculitides (SVV).

The new definitions are consensus based and do not derive from the SLR. They differ in some details from definitions used in recent clinical trials (for comparison see online supplementary file 2). By analogy to the EULAR definitions for SVV, we suggest using the term ‘relapse’ consistently, but avoiding the term ‘flare’. We propose a distinction between major and minor relapses because the prognosis and treatment of relapses in LVV depends on the presence of ischaemia and/or development or progression of vascular damage. In contrast to SVV, true refractory disease in LVV is very rare because patients usually respond well to high dose glucocorticoids (GCs). However, in the past, the term ‘refractory’ was sometimes used for patients with LVV and GC-dependent disease that relapsed when GCs were tapered. We propose that the activity state ‘refractory’ should be used to reflect the difficulty in achieving disease control despite the patient remaining on an appropriate treatment schedule (which would include tapering of the GC dose).

In 2012, IgG4-related (peri-)aortitis and isolated aortitis, either primary or secondary to infection (eg, syphilis) or other systemic diseases were recognised as separate entities by the Chapel Hill consensus conference. The SLR revealed only very low evidence on management of these rare entities, which did not allow us to generate separate recommendations. Therefore, we encourage further research on these subtypes, as outlined in the research agenda below.

Overarching principles
The task force identified general principles that were deemed fundamental for the management of patients with LVV (table 3). These principles were consensus based and did not directly result from the SLR. The overarching principles and the specific recommendations are listed in table 3.

Recommendations
All patients presenting with signs and symptoms suggestive of GCA should be urgently referred to a specialist team for further multidisciplinary diagnostic work-up and management.

Untreated active GCA is an emergency and carries a substantial risk of permanent visual loss and other ischaemic complications. Therefore, we recommend that all patients ≥50 years of age presenting with acute or subacute onset of signs and symptoms suggestive of GCA should be urgently referred to a specialist team.

Table 1 Topics for the systematic literature search

<table>
<thead>
<tr>
<th>SLR 1: General Management</th>
<th>SLR 2: Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis: recognition, referral criteria, fast-track diagnosis, role of imaging for diagnosis, role of biopsy for diagnosis, interdisciplinary work-up, considerations for sub-types of disease such as cranial/ischaeimic/large vessel, isolated aortitis, IgG4-related disease, LVV disease in other vasculitides.</td>
<td>Drug therapy: dosing, length of therapy, outcome and treatment-related side effects for the following drugs: glucocorticoids, methotrexate and other non-biological immunosuppressive agents, tocilizumab and other biological agents.</td>
</tr>
<tr>
<td>Prognostic and therapeutic implications of disease phenotypes: cranial vs extra-cranial, isolated aortitis, other forms including IgG-4 related disease, imaging, other biomarkers, comorbidities and complications, disease damage versus activity.</td>
<td>Specific treatment of organ complications: loss of vision and stroke, relapsing, refractory, glucocorticoid-dependent disease.</td>
</tr>
<tr>
<td>Long-term follow-up of patients: clinical assessments and frequency, imaging, patient-reported outcomes, physical therapies and management of complications.</td>
<td>Revascularisation procedures: indications for referral, management of aneurysms and/or vessel stenosis.</td>
</tr>
</tbody>
</table>

LVV, large vessel vasculitides; SLR, systematic literature review.

Table 2 EULAR consensus definitions for disease activity states in GCA and other types of LVV

<table>
<thead>
<tr>
<th>Activity state</th>
<th>EULAR consensus definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active disease</td>
<td>1. The presence of typical signs or symptoms of active LVV (table 3). 2. At least one of the following: a. Current activity on imaging or biopsy. b. Ischaemic complications attributed to LVV. c. Persistently elevated inflammatory markers (after other causes have been excluded).</td>
</tr>
<tr>
<td>Flare</td>
<td>We do not recommend use of this term</td>
</tr>
<tr>
<td>Relapse</td>
<td>We recommend use of the terms major relapse or minor relapse as defined below</td>
</tr>
<tr>
<td>Major relapse</td>
<td>Recurrence of active disease with either of the following: a. Clinical features of ischaemia (including jaw claudication, visual symptoms, visual loss attributable to GCA, scalp necrosis, stroke, limb claudication). b. Evidence of active aortic inflammation resulting in progressive aortic or large vessel dilatation, stenosis or dissection.</td>
</tr>
<tr>
<td>Minor relapse</td>
<td>Recurrence of active disease, not fulfilling the criteria for a major relapse</td>
</tr>
<tr>
<td>Refractory</td>
<td>Inability to induce remission (with evidence of reactivation of disease, as defined above in 'Active disease') despite the use of standard care therapy</td>
</tr>
<tr>
<td>Remission</td>
<td>Absence of all clinical signs and symptoms attributable to active LVV and normalisation of ESR and CRP; in addition, for patients with extracranial disease there should be no evidence of progressive vessel narrowing or dilatation (frequency of repeat imaging to be decided on an individual basis)</td>
</tr>
<tr>
<td>Sustained remission</td>
<td>1. Remission for at least 6 months. 2. Achievement of the individual target GC dose.</td>
</tr>
<tr>
<td>Glucocorticoid-free remission</td>
<td>Sustained remission Discontinued GC therapy (but could still be receiving other immunosuppressive therapy)</td>
</tr>
</tbody>
</table>

*Some symptoms listed are typical only for GCA and may require further diagnostic work-up if present in other types of LVV. GC, glucocorticoid; GCA, giant cell arteritis; LVV, large vessel vasculitides.
symptoms suggestive of GCA (table 4) and raised inflammatory markers without explanation (eg, infection) should be referred urgently to a specialist team/experienced centre for further diagnostic work-up. This team or centre should have expertise in the disease, have rapid access to up-to-date imaging and temporal artery biopsy (TAB) and should offer fast referral. Patients with new onset of visual symptoms should be seen as soon as possible by an ophthalmological team to exclude other causes of sudden visual disturbance. In case of signs of cerebral ischaemia, rapid referral in order to confirm the diagnosis of GCA is recommended.11

For patients without visual symptoms, there was no consensus among the task force members as to whether pre-emptive treatment with GCS should be started in all cases of suspected GCA in addition to fast referral to a specialised centre. In any case, pre-emptive therapy should only be given for a short period of time and should not delay early referral because the sensitivity of diagnostic tests decreases following treatment with GCSs and to avoid unnecessary exposure to GCSs of cases for whom the diagnosis of GCA is eventually not maintained. Although, the sensitivity of diagnostic tests decreases following treatment, imaging and biopsy may show features of GCA even weeks after GCS therapy.3,14–16 Therefore, diagnostic tests to confirm a suspected diagnosis of GCA should be performed in all patients irrespective of the duration of pre-emptive therapy.

All patients presenting with signs and symptoms suggestive of TAK should be referred to a specialist team for multidisciplinary diagnostic work-up and management. The majority of symptoms of TAK (table 4) are non-specific, but should prompt a thorough examination of the arterial tree. Because there is no gold standard for the diagnosis of TAK,

Table 3 EULAR recommendations for the management of LVV—2018 update

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>LoE</th>
<th>SoR</th>
<th>FV (%)</th>
<th>LoA (0–10)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overarching principles</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Patients with LVV should be offered best care which must be based on a shared decision between the patient and the rheumatologist, considering efficacy, safety and costs</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>9.7±0.7</td>
</tr>
<tr>
<td>B Patients should have access to education focusing on the impact of LVV, its key warning symptoms and its treatment (including treatment-related complications)</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>9.7±0.7</td>
</tr>
<tr>
<td>C Patients with LVV should be screened for treatment-related and cardiovascular comorbidities. We recommend prophylaxis and lifestyle advice to reduce cardiovascular risk and treatment-related complications</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>9.8±0.7</td>
</tr>
<tr>
<td><strong>Recommendations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 All patients presenting with signs and symptoms suggestive of GCA should be urgently referred to a specialist team for further multidisciplinary diagnostic work-up and management</td>
<td>2b</td>
<td>C</td>
<td>91</td>
<td>9.2±2.1</td>
</tr>
<tr>
<td>2 All patients presenting with signs and symptoms suggestive of TAK should be referred to a specialist team for multidisciplinary diagnostic work-up and management</td>
<td>5</td>
<td>D</td>
<td>100</td>
<td>9.6±0.9</td>
</tr>
<tr>
<td>3 A suspected diagnosis of LVV should be confirmed by imaging (ultrasound* or MRI† for temporal or other cranial arteries, ultrasound, CT, PET-CT or MRI for the aorta/extracranial arteries‡) or histology (TAB*)</td>
<td>*1b</td>
<td>*A</td>
<td>*100</td>
<td>9.5±0.9</td>
</tr>
<tr>
<td></td>
<td>†1b</td>
<td>†B</td>
<td>†100</td>
<td>9.3±1.2</td>
</tr>
<tr>
<td></td>
<td>‡1c</td>
<td>‡C</td>
<td>‡100</td>
<td>9.6±0.8</td>
</tr>
<tr>
<td>4 High dose glucocorticoid (GC) therapy (40–60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active GCA* or TAK†</td>
<td>*4</td>
<td>*C</td>
<td>*100</td>
<td>9.8±0.6</td>
</tr>
<tr>
<td>Once disease is controlled, we recommend tapering the GC dose to a target dose of 15–20 mg/day within 2–3 months and after 1 year to ≤5 mg/day (for GCA) and to ≤10 mg/day (for TAK)</td>
<td>4</td>
<td>5</td>
<td>87</td>
<td>9.5±0.9</td>
</tr>
<tr>
<td>5 Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GC related adverse effects or complications) using tocilizumab**, Methotrexate may be used as an alternative††</td>
<td>*1b</td>
<td>**A</td>
<td>*100</td>
<td>9.4±0.8</td>
</tr>
<tr>
<td></td>
<td>†1a-</td>
<td>††A</td>
<td>††100</td>
<td>9.4±0.8</td>
</tr>
<tr>
<td>6 Non-biologic disease modifying agents should be given in combination with GC in all patients with TAK*. Tocilizumab or TNF-inhibitors can be considered in case of relapsing or refractory disease despite conventional DMARD therapy*</td>
<td>4</td>
<td>C</td>
<td>100</td>
<td>9.4±1.2</td>
</tr>
<tr>
<td>7 In case of major relapse (either with signs or symptoms of ischaemia or progressive vascular inflammation) we recommend reinitiation or dose escalation of GC therapy as recommended for new onset disease. For minor relapses we recommend an increase in GC dose at least to the last effective dose. * Initiation or modification of adjunctive therapy should be considered particularly after recurrent disease relapses*</td>
<td>*2b</td>
<td>*A</td>
<td>*95</td>
<td>9.5±1.0</td>
</tr>
<tr>
<td></td>
<td>†1b</td>
<td>†A</td>
<td>†95</td>
<td>9.6±1.0</td>
</tr>
<tr>
<td>8 Antiplatelet or anticoagulant therapy should not be routinely used for treatment of LVV unless it is indicated for other reasons (eg, coronary heart disease or cerebrovascular disease etc). In special situations such as vascular ischaemic complications or high risk of cardiovascular disease, these might be considered on an individual basis</td>
<td>4</td>
<td>C</td>
<td>100</td>
<td>9.4±0.8</td>
</tr>
<tr>
<td>9 In LVV, elective endovascular interventions or reconstructive surgery should be performed in phases of stable remission. However, arterial vessel dissection or critical vascular ischaemia requires urgent referral to a vascular team</td>
<td>4</td>
<td>C</td>
<td>95</td>
<td>9.8±0.5</td>
</tr>
<tr>
<td>10 Regular follow-up and monitoring of disease activity in patients with LVV is recommended, primarily based on symptoms, clinical findings and ESR/CRP levels</td>
<td>3b</td>
<td>C</td>
<td>100</td>
<td>9.6±0.6</td>
</tr>
</tbody>
</table>

The LoE was determined for different parts of each recommendation (referred to with different signs such as * or †). The level of agreement was computed on a 0–10 scale. DMARD, disease modifying anti-rheumatic drug; FV, final vote (% of expert panel members that agreed to the recommendation); LVV, large vessel vasculitis; LoE, level of agreement; LoA, level of evidence; NA, not applicable; SoR, strength of recommendation; TAB, temporal artery biopsy; TAK, Takayasu arteritis; TNF, tumour necrosis factor.

---

**Table 4**

<table>
<thead>
<tr>
<th>Description</th>
<th>LoE</th>
<th>SoR</th>
<th>FV (%)</th>
<th>LoA (0–10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with LVV presenting with typical symptoms (headache, jaw claudication, visual disturbance) should be offered GC therapy promptly as diagnosis of LVV should be confirmed by TAB</td>
<td>2a</td>
<td>C</td>
<td>95</td>
<td>9.8±0.7</td>
</tr>
<tr>
<td>Patients with LVV presenting with atypical symptoms, clinical findings and ESR/CRP levels</td>
<td>3b</td>
<td>C</td>
<td>100</td>
<td>9.6±0.6</td>
</tr>
<tr>
<td>Patients with LVV and LVV-related complications (cardiovascular disease, cerebrovascular disease etc)</td>
<td>4</td>
<td>C</td>
<td>100</td>
<td>9.4±1.2</td>
</tr>
<tr>
<td>Patients with LVV and LVV-related complications (cardiovascular disease, cerebrovascular disease etc) should be managed in a multidisciplinary setting</td>
<td>5</td>
<td>D</td>
<td>100</td>
<td>9.6±0.9</td>
</tr>
</tbody>
</table>

*LoE 1 represents a strong recommendation and LoE 5 represents a weak recommendation. SoR A represents a strong recommendation. SoR D represents a weak recommendation. FV represents the level of agreement.*
of the contralateral artery does not add significantly to the diagnostic yield and is therefore not routinely recommended. Overall, available data do not provide convincing evidence that any individual characteristics of the biopsy findings (eg, composition or intensity of the inflammatory infiltrate) are sufficiently predictive for subsequent clinical events to allow guidance of treatment decisions or follow-up in clinical practice.\textsuperscript{21–35}

ESR and CRP are typically elevated in GCA, and it is highly infrequent (<3%) that both are normal.\textsuperscript{36–37} While several other serological biomarkers have been evaluated, none is sufficiently sensitive and specific for detection and assessment of disease activity or prediction of prognosis to recommend its use in clinical practice.

In patients with atypical clinical presentations not compatible with current disease definitions,\textsuperscript{3} an alternative diagnosis or overlapping associated diseases should be considered, in the diagnostic work up, such as for example aortitis related to IgG4-related disease, LVV in anti-neutrophil-cytoplasm (ANCA)-associated vasculitis (AAV) or other vasculitides (eg, Behçet’s syndrome), or LVV secondary to spondyloarthropathies, relapsing polychondritis or infections.

High dose GC therapy (40–60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active GCA or TAK. Once disease is controlled, we recommend tapering the GC dose to a target dose of 15–20 mg/day within 2–3 months and after 1 year to ≤5 mg/day (for GCA) and to ≤10 mg/day (for TAK). Induction treatment with a starting GC dose of 40–60 mg per day (all GC doses discussed in this article are prednisolone equivalents) leads to remission in the majority of patients with LVV.\textsuperscript{38–43} Although the maximum genomic effect of GCs is around 100 mg of prednisolone-equivalent,\textsuperscript{44} there is no clear evidence that starting doses of above 60 mg per day are more effective than 60 mg per day in the prevention of ischaemic events or other relevant endpoints. It should be noted that the genomic effects of glucocorticoids depend on certain patient-specific pharmacokinetic and pharmacodynamic factors. These include for example total cell number (indirectly quantified by weight), numbers of glucocorticoid receptors per cell, and glucocorticoid receptor binding affinity.\textsuperscript{45–46} The relatively high variability of these factors explains why neither the dose-dependent efficacy of a glucocorticoid therapy can be predicted absolutely correctly, nor a weight-adapted therapy with glucocorticoids is recommended. As a consequence, and since differences between certain dosages or weight-adapted glucocorticoid dosages have not been rigorously tested in clinical trials, the current recommendations provide dose ranges.

In patients with GCA with acute visual loss or amaurosis fugax, the administration of 0.25–1 g intravenous methylprednisolone for up to 3 days should be considered, because these high doses have both genomic and rapid non-genomic effects.\textsuperscript{44} However, there are only low-quality retrospective clinical data supporting this recommendation.\textsuperscript{47–49} Referral for intravenous GC therapy should not delay treatment with oral GC. The SLR revealed quality issues in both randomised controlled clinical trials (RCTs) of high dose pulse intravenous GC therapy in patients without visual symptoms.\textsuperscript{50–51} In view of the limited quality of evidence, the task force recommends limiting the use of intravenous pulse GC therapy to patients with complicated GCA such as those with GCA-related visual symptoms.

We recommend tapering the GC dose, once remission has been achieved. A GC taper regimen must weigh the risk of relapse against the risk of GC-related adverse events. In GCA, relapses
2018 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF GIANT CELL ARTERITIS

**Figure 1** The 2018 EULAR algorithm for pharmacological treatment of giant cell arteritis (GCA). GC, glucocorticoids. A clinical diagnosis of GCA should be confirmed by either imaging or biopsy; acute loss of vision, amaurosis fugax; or 5–15 mg/day above the last effective dose; the treatment target is sustained remission (absence of clinical signs and symptoms of active GCA + normal acute phase reactants) plus ability to taper GCs to the specified target without relapse; see Table 2 for definitions; recommended dose is 162 mg; minimum recommended dose is 15 mg to be decided on an individual basis (lack of evidence); in patients with GCA-related visual symptoms consider a starting dose of 60 mg prednisone per day after GC administration.

Adjuvant therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GCA-related adverse effects or complications) using TCZ. Methotrexate may be used as an alternative.

The original recommendations suggested adjuvant immunosuppressive therapy in all patients with LVV. However, although the risk of relapse in GCA is high, a substantial number of patients with GCA treated with GC monotherapy do not relapse and are able to taper the GC dose according to a target of ≤5 mg/day after 1 year, and some authors advocate tapering the GC dose to ≤5 mg/day after 1 year (Figure 1). Despite the lack of data regarding the optimal length of GC therapy, the majority of panel members reported that it usually takes about 2 years or more before GCs can be stopped. In patients receiving GC-sparing therapy, faster GC taper and earlier withdrawal of GCs should be considered on an individual basis, given the lack of data. In patients treated with TCZ, the published rapid 26-week GC taper may be attempted in order to significantly reduce the cumulative dose. It is not known if even faster or conversely more prolonged GC withdrawal during TCZ therapy may lead to improved outcomes.

For TAK, there are no studies comparing different GC taper protocols. Clinical experience suggests that a starting dose of 40–60 mg per day is appropriate for the majority of patients, while patients with more localised disease may respond to lower initial GC doses of 25–30 mg per day. In a recent small RCT of TCZ in TAK, a taper of GC in the placebo group by 10% per week after week four resulted in a high relapse rate (around 80% during weeks 8–16). A similar relapse rate in TAK patients treated with GC monotherapy was observed in a recent RCT of abatacept. Therefore, we recommend that in patients who have reached a GC dose of 15–20 mg/day after 2–3 months, GC doses should subsequently be reduced more slowly as compared with GCA, targeting a dose of ≤10 mg/day after 1 year (Figure 2).

Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GCA-related adverse effects or complications) using TCZ. Methotrexate may be used as an alternative.

The original recommendations suggested adjuvant immunosuppressive therapy in all patients with LVV. However, although the risk of relapse in GCA is high, a substantial number of patients with GCA treated with GC monotherapy do not relapse and are able to taper the GC dose according to a target of ≤5 mg/day after 1 year, and some authors advocate tapering the GC dose to ≤5 mg/day after 1 year (Figure 1). Despite the lack of data regarding the optimal length of GC therapy, the majority of panel members reported that it usually takes about 2 years or more before GCs can be stopped. In patients receiving GC-sparing therapy, faster GC taper and earlier withdrawal of GCs should be considered on an individual basis, given the lack of data. In patients treated with TCZ, the published rapid 26-week GC taper may be attempted in order to significantly reduce the cumulative dose. It is not known if even faster or conversely more prolonged GC withdrawal during TCZ therapy may lead to improved outcomes.

For TAK, there are no studies comparing different GC taper protocols. Clinical experience suggests that a starting dose of 40–60 mg per day is appropriate for the majority of patients, while patients with more localised disease may respond to lower initial GC doses of 25–30 mg per day. In a recent small RCT of TCZ in TAK, a taper of GC in the placebo group by 10% per week after week four resulted in a high relapse rate (around 80% during weeks 8–16). A similar relapse rate in TAK patients treated with GC monotherapy was observed in a recent RCT of abatacept. Therefore, we recommend that in patients who have reached a GC dose of 15–20 mg/day after 2–3 months, GC doses should subsequently be reduced more slowly as compared with GCA, targeting a dose of ≤10 mg/day after 1 year (Figure 2).

Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GCA-related adverse effects or complications) using TCZ. Methotrexate may be used as an alternative.

The original recommendations suggested adjuvant immunosuppressive therapy in all patients with LVV. However, although the risk of relapse in GCA is high, a substantial number of patients with GCA treated with GC monotherapy do not relapse and are able to taper the GC dose according to a target of ≤5 mg/day after 1 year, and some authors advocate tapering the GC dose to ≤5 mg/day after 1 year (Figure 1). Despite the lack of data regarding the optimal length of GC therapy, the majority of panel members reported that it usually takes about 2 years or more before GCs can be stopped. In patients receiving GC-sparing therapy, faster GC taper and earlier withdrawal of GCs should be considered on an individual basis, given the lack of data. In patients treated with TCZ, the published rapid 26-week GC taper may be attempted in order to significantly reduce the cumulative dose. It is not known if even faster or conversely more prolonged GC withdrawal during TCZ therapy may lead to improved outcomes.

For TAK, there are no studies comparing different GC taper protocols. Clinical experience suggests that a starting dose of 40–60 mg per day is appropriate for the majority of patients, while patients with more localised disease may respond to lower initial GC doses of 25–30 mg per day. In a recent small RCT of TCZ in TAK, a taper of GC in the placebo group by 10% per week after week four resulted in a high relapse rate (around 80% during weeks 8–16). A similar relapse rate in TAK patients treated with GC monotherapy was observed in a recent RCT of abatacept. Therefore, we recommend that in patients who have reached a GC dose of 15–20 mg/day after 2–3 months, GC doses should subsequently be reduced more slowly as compared with GCA, targeting a dose of ≤10 mg/day after 1 year (Figure 2).

Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GCA-related adverse effects or complications) using TCZ. Methotrexate may be used as an alternative.

The original recommendations suggested adjuvant immunosuppressive therapy in all patients with LVV. However, although the risk of relapse in GCA is high, a substantial number of patients with GCA treated with GC monotherapy do not relapse and are able to taper the GC dose according to a target of ≤5 mg/day after 1 year, and some authors advocate tapering the GC dose to ≤5 mg/day after 1 year (Figure 1). Despite the lack of data regarding the optimal length of GC therapy, the majority of panel members reported that it usually takes about 2 years or more before GCs can be stopped. In patients receiving GC-sparing therapy, faster GC taper and earlier withdrawal of GCs should be considered on an individual basis, given the lack of data. In patients treated with TCZ, the published rapid 26-week GC taper may be attempted in order to significantly reduce the cumulative dose. It is not known if even faster or conversely more prolonged GC withdrawal during TCZ therapy may lead to improved outcomes.

For TAK, there are no studies comparing different GC taper protocols. Clinical experience suggests that a starting dose of 40–60 mg per day is appropriate for the majority of patients, while patients with more localised disease may respond to lower initial GC doses of 25–30 mg per day. In a recent small RCT of TCZ in TAK, a taper of GC in the placebo group by 10% per week after week four resulted in a high relapse rate (around 80% during weeks 8–16). A similar relapse rate in TAK patients treated with GC monotherapy was observed in a recent RCT of abatacept. Therefore, we recommend that in patients who have reached a GC dose of 15–20 mg/day after 2–3 months, GC doses should subsequently be reduced more slowly as compared with GCA, targeting a dose of ≤10 mg/day after 1 year (Figure 2).

Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GCA-related adverse effects or complications) using TCZ. Methotrexate may be used as an alternative.

The original recommendations suggested adjuvant immunosuppressive therapy in all patients with LVV. However, although the risk of relapse in GCA is high, a substantial number of patients with GCA treated with GC monotherapy do not relapse and are able to taper the GC dose according to a target of ≤5 mg/day after 1 year, and some authors advocate tapering the GC dose to ≤5 mg/day after 1 year (Figure 1). Despite the lack of data regarding the optimal length of GC therapy, the majority of panel members reported that it usually takes about 2 years or more before GCs can be stopped. In patients receiving GC-sparing therapy, faster GC taper and earlier withdrawal of GCs should be considered on an individual basis, given the lack of data. In patients treated with TCZ, the published rapid 26-week GC taper may be attempted in order to significantly reduce the cumulative dose. It is not known if even faster or conversely more prolonged GC withdrawal during TCZ therapy may lead to improved outcomes.

For TAK, there are no studies comparing different GC taper protocols. Clinical experience suggests that a starting dose of 40–60 mg per day is appropriate for the majority of patients, while patients with more localised disease may respond to lower initial GC doses of 25–30 mg per day. In a recent small RCT of TCZ in TAK, a taper of GC in the placebo group by 10% per week after week four resulted in a high relapse rate (around 80% during weeks 8–16). A similar relapse rate in TAK patients treated with GC monotherapy was observed in a recent RCT of abatacept. Therefore, we recommend that in patients who have reached a GC dose of 15–20 mg/day after 2–3 months, GC doses should subsequently be reduced more slowly as compared with GCA, targeting a dose of ≤10 mg/day after 1 year (Figure 2).

Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GCA-related adverse effects or complications) using TCZ. Methotrexate may be used as an alternative.

The original recommendations suggested adjuvant immunosuppressive therapy in all patients with LVV. However, although the risk of relapse in GCA is high, a substantial number of patients with GCA treated with GC monotherapy do not relapse and are able to taper the GC dose according to a target of ≤5 mg/day after 1 year, and some authors advocate tapering the GC dose to ≤5 mg/day after 1 year (Figure 1). Despite the lack of data regarding the optimal length of GC therapy, the majority of panel members reported that it usually takes about 2 years or more before GCs can be stopped. In patients receiving GC-sparing therapy, faster GC taper and earlier withdrawal of GCs should be considered on an individual basis, given the lack of data. In patients treated with TCZ, the published rapid 26-week GC taper may be attempted in order to significantly reduce the cumulative dose. It is not known if even faster or conversely more prolonged GC withdrawal during TCZ therapy may lead to improved outcomes.
Two high-quality randomised controlled clinical trials in patients with GCA have shown that adjunctive administration of TCZ reduces the risk of relapse and cumulative GC exposure compared with GC monotherapy. Because TCZ suppresses CRP synthesis in the liver, the presence of a normal CRP or ESR may be falsely reassuring, although sensitivity analyses in the GiACTA trial suggest that this problem did not affect the primary outcome. However, with the limited reliability of acute phase reactants for activity assessment in patients receiving TCZ, follow-up is largely symptom-based, which can make monitoring disease activity difficult. Thus, further studies on the role of imaging and other biomarkers for disease monitoring are needed. As high-quality long-term data are missing, it is not known if TCZ can reduce the risk of aneurysms or vascular stenosis. Hypothetically, the development of vascular long-term damage may occur despite TCZ therapy.

Of three RCTs on the use of methotrexate (MTX) in newly diagnosed GCA, only one met its primary endpoint. As outlined in our SLR analysis in more detail, all of these trials were conducted more than 20 years ago, had differences in the study design and sample size which could have all accounted for the divergent outcomes. Importantly, the maximum weekly MTX doses of 7.5, 10 and 15 mg p.o. used in all three studies were lower than those used in clinical practice today. Despite methodological limitations of the individual studies, a high quality meta-analysis using pooled individual patient data from these trials demonstrated a reduced risk of first relapse (HR 0.65, 95% CI 0.44 to 0.98, p=0.04) and second relapse (HR 0.49, 95% CI 0.27 to 0.89, p=0.02), a higher probability of GC-free remission for ≥24 weeks (HR 2.84, 95% CI 1.52 to 5.28, p<0.001) and a lower cumulative GC dose of ~842 mg at week 48 in patients treated with MTX versus controls. Of note, adverse events and early withdrawals were not different between MTX and placebo groups in the metaanalysis.

There are no trials comparing TCZ and MTX in GCA and the differing study designs preclude strong conclusions about the potential superiority of one agent over the other. However, compared with MTX, the effect size of TCZ in terms of relapse risk reduction and GC sparing seems larger and the meta-analysis on MTX revealed heterogeneity of results between the individual studies. Therefore, TCZ provides a higher confidence in achieving a clinically relevant treatment effect as compared with MTX. Further studies are needed to define the optimal length of treatment, GC taper regimens, cost effectiveness and monitoring. At present, there are few and only low-quality data on long-term treatment with MTX or TCZ in GCA. Therefore, the duration of treatment and potential dose reductions must be decided on an individual basis. As current evidence does not suggest an excessive risk of treatment-related complications of TCZ or MTX as compared with other indications, patients should be monitored for treatment-related side effects according to existing guidelines for other diseases.

Data for other adjunctive therapies are either sparse (abatacept), derived from low-quality studies (ustekinumab, azathioprine, leflunomide, cyclophosphamide, dapsone, etanercept) or negative (adalimumab, infliximab, cyclosporine).

Non-biological disease modifying agents should be given in combination with GC in all patients with TAK. TCZ or tumour necrosis factor-inhibitors can be considered in case of relapsing or refractory disease despite conventional disease modifying anti-rheumatic drug therapy.

In view of the high relapse rates of up to 70%, the development of new vascular lesions and the inability of many patients to achieve low GC doses, we advise that early administration of a GC-sparing agent in TAK is justified and reflects current treatment practice in more recent cohorts. However, we acknowledge that the LoE supporting this recommendations is low.

Only two RCTs, both on biological agents, have been published, neither of which met its primary endpoint for efficacy. The evidence for a use of TCZ in TAK comes largely from one small RCT showing a statistically borderline significant improvement in some secondary endpoints in the TCZ-treated patients. Additional...
experience with TCZ treatment in TAK was reported from one prospective and four retrospective case series including a total of 89 patients of which the majority had refractory or relapsing disease despite treatment with GC or other agents. 93–100 Efficacy of tumour necrosis factor (TNF)-inhibitors in TAK has been reported in one prospective and several retrospective open-label uncontrolled studies/case series. 101–111 Overall, the reported reductions in disease activity in all these case series need to be interpreted with caution, because disease activity in TAK may decrease as a result of continued GC therapy over time. In contrast to the positive trends observed in GCA, the RCT of abatacept did not show any signs of efficacy in TAK. 112 Lower quality evidence from uncontrolled prospective and retrospective case series exists for the use of conventional immunosuppressive agents such as MTX, leflunomide, mycophenolate mofetil, azathioprine and cyclophosphamide in TAK. 112–117 Since TAK targets primarily women with childbearing potential and is a chronic and usually not acutely life threatening disease (unlike AAV), the use of cyclophosphamide should be limited to patients where other treatments have failed or are not tolerated. There is no high-quality evidence showing superiority of biologicals over conventional disease modifying anti-rheumatic drugs (DMARDs) in TAK.

Despite this overall low LoE, we recommend considering adjunctive treatment with conventional immunosuppressive drugs at diagnosis of TAK. A TNF-inhibitor or TCZ can be used as second line agents in case of relapsing disease. The choice of a specific immunosuppressive agent should be based on patient comorbidities or contraindications. GCs should be tapered to the lowest possible dose during treatment with immunosuppressive agents. Because good-quality data on long-term treatment of TAK are lacking, the duration of treatment must be decided on an individual basis. One study indicated that relapse risk is particularly high during the first 5 years following diagnosis. 92

In case of major relapse (either with signs or symptoms of ischaemia or progressive vascular inflammation) we recommend reinstitution or dose escalation of GC therapy as recommended for new onset disease. For minor relapses we recommend an increase in GC dose to at least the last effective dose. Initiation or modification of adjunctive therapy should be considered particularly after recurrent disease relapses.

There are no studies specifically addressing the treatment of relapse in LVV. Even larger cohort studies on relapses in GCA often lack detailed information on treatment of the relapse (GC dose, tapering, initiation of adjunctive treatment, etc). 30, 51 Protocols for relapse treatment differ among RCTs and the heterogeneous study designs and adjunctive therapies do not allow for robust conclusions regarding which of the different strategies is the best.

Major relapses impose the risk of subsequent organ damage due to ischaemia and/or progressive vascular inflammation (eg, progressive large vessel stenosis) and should therefore be treated like new-onset disease with high dose GC (initial dose 40–60 mg/day) as outlined above (recommendations 3 and 4). In case of a minor relapse (eg, recurring isolated polymyalgia rheumatica (PMR) symptoms), we recommend an increase of the daily GCs dose either to the last effective dose or to 5–15 mg above this dose, the latter being common practice in many centres.

Disease relapses in LVV are most commonly but not always accompanied by an increase of ESR and CRP. 49, 51, 52, 118 In the absence of symptoms of LVV, a rise of ESR or CRP should not automatically prompt an immediate escalation of immunosuppressive therapy. Infections should be ruled out first. If repeated measurements confirm a substantial elevation of ESR and CRP and if there is no evidence for another cause of the inflammatory response, large vessel imaging should be considered. In the presence of less specific symptoms (eg, diffuse headache) in patients with normal inflammatory markers,
imaging (ultrasound, MRI or PET-CT) may be helpful. However, signals of vessel wall inflammation on imaging may persist even in complete clinical remission. At present, it is unknown if such residual activity represents true active disease or remoulding. Therefore, such imaging findings observed during follow-up have to be interpreted with caution considering the disease course of the individual patient and by comparing them to imaging findings previously obtained.

As outlined in recommendation 5, we recommend adjunctive GC sparing therapy (if not already begun at disease onset) or a modification (dose escalation or switch to another agent) of an already existing GC-sparing therapy in relapsing patients in order to improve long-term disease control. So far, there are no RCTs that have specifically focused on the adjunctive treatment of relapses. However, the GIACTA trial included 132 relapsing patients and TCZ was superior to GC monotherapy in this situation. All three RCTs of MTX in GCA included patients with new onset disease only. However, patients who received MTX had a 50% lower risk (p=0.02) of developing a second relapse in a meta-analysis, thus providing evidence for the efficacy of MTX after a first relapse. Other agents have either not been studied prospectively or showed no signs of efficacy in relapsing GCA.

In relapsing TAK despite treatment with GC plus a conventional immunosuppressive agent, a TNF-inhibitor or TCZ can be used as second line agent (see also recommendation 6).

Antiplatelet or anticoagulant therapy should not be routinely used for treatment of LVV unless it is indicated for other reasons (eg, coronary heart disease, cerebrovascular disease, etc). In special situations such as vascular ischaemic complications or high risk of cardiovascular disease, these might be considered on an individual basis.

Patients with GCA are at an increased risk of developing cardiovascular and cerebrovascular events. The original EULAR recommendation to use aspirin prophylactically in GCA was based on data from two retrospective studies showing that patients who received low-dose aspirin before or at the time of diagnosis of GCA may have reduced rates of vision loss or stroke, although the number of events was low in these cohorts. However, two more recent cohort studies and a meta-analysis did not confirm a protective effect of aspirin in GCA. Balancing the potential protective effect (which is unknown) of aspirin against its potential harm (such as bleeding), we decided to change the original statement and now recommend that antiplatelet or anticoagulant therapy should not be routinely prescribed unless they are indicated for other reasons (eg, coronary heart disease, cerebrovascular disease, etc).

A significantly decreased risk of ischaemic events was reported from a single cohort of 41 TAK patients using antiplatelet therapy. In view of the low LoE, a vascular team should decide on the use of anti-platelet therapy in TAK on an individual basis taking the degree of vessel stenosis and other risk factors into account.

In LVV, elective endovascular interventions or reconstructive surgery should be performed during stable remission. However, arterial vessel dissection or critical vascular ischaemia requires urgent referral to a vascular team.

Interventional or surgical therapy is indicated if a vascular lesion that persists despite medical therapy is either symptomatic (such as a peripheral artery limb stenosis causing claudication) or is associated with an increased risk of future complications (such as rapid progression of an aortic aneurysm). The method of choice for vascular interventions in patients with LVV depends on the anatomic location of the vascular damage, timing (elective vs emergency) and other factors.

Undertaking surgical interventions in patients with active disease is associated with an increased risk of complications and lower patency rates. Procedures should preferably be performed only during stable control of inflammation, except for emergency indications such as critical ischaemia, neurological complications such as stroke or aneurysm dissection. Otherwise, interventional and surgical vascular therapy follows the same principles as in patients without vasculitis. Given the complexity of LVV, patients selected for interventional or surgical therapy should be managed in collaboration with a multidisciplinary team (the exact constituency will vary, but could include vascular radiologists, vascular surgeons, neurologists and rheumatologists).

Regular follow-up and monitoring of disease activity is recommended in patients with LVV, primarily based on symptoms, clinical findings and ESR/CRP levels.

There are no data available to guide long-term follow-up of patients with GCA or TAK. In view of the high frequency of relapses and the potential harm resulting from relapse-related vessel and organ damage, routine follow-up visits could be scheduled every 1–3 months during the first year and in 3–6 months intervals afterwards. In patients with relapse-free remission, annual follow-up under shared care between rheumatologists and primary care can be considered. As late relapses can occur and the incidence of structural vascular lesions in GCA increases after 5 years from diagnosis, long-term follow-up of patients with GCA that remain asymptomatic can be scheduled on an individual patient basis.

Visits should include clinical monitoring and measurement of ESR and CRP. Routine imaging for activity assessment is not recommended for patients in clinical and biochemical remission, but may be used for long-term monitoring of structural damage, particularly vessel stenosis, dilation and/or aneurysms. Methods and frequency of imaging should be decided on an individual basis. LVV-specific patient-reported outcome instruments for use in clinical practice are not available, and should be the subject of future research.

DISCUSSION

Since the first EULAR recommendations on the management of LVV were published, high-quality diagnostic studies and several RCTs have expanded our knowledge about these complex diseases and allowed a significant update of the original recommendations. In view of new research questions to be addressed, improvements in SOPs and methodology for the development of EULAR recommendations, we undertook two completely new SLRs without time limits. Therefore, this update represents a new set of recommendations rather than a simple revision. While the majority of the original recommendations addressed LVV in general, new data allowed us to offer separate recommendations for GCA and TAK at least for some key areas of management. In GCA, disease subsets with only cranial, only extracranial or cranial plus extracranial arteritis have been described. High-quality evidence to guide differential management of these subtypes is yet lacking. Therefore,
all recommendations on GCA management inhere refer to all subtypes of GCA.

For this update, we have made substantial alterations, including the introduction of overarching principles and new recommendations on early diagnosis, multidisciplinary management and relapse treatment.

In conclusion, we substantially revised the original recommendations for the management of LVV. Despite progress over the past 10 years, we acknowledge that many recommendations are still consensus-based. However, despite the low-LoE, the level of agreement for each recommendation was consistently high among the task force members. We encourage clinicians to implement these recommendations into their clinical practice in order to effectively manage LVV and to improve the patients’ quality of care.

Author affiliations
1Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim-Teck, Germany
2Rheumatology Department, Centro Hospitalar do Baixo Vouga E.P.E, Aveiro, Portugal
3Rheumatology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
4Department of Rheumatology and Immunology, University Hospital Charité, Berlin, Germany
5Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, Basse-Normandie, France
6Rheumatology and Clinical Immunology, UMC Groningen, The Netherlands
7Leicester, UK
8Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
9Rheumatology, Southend Hospital NHS Trust, Westcliff-on-sea, UK
10Rheumatology, Medical University Graz, Graz, Austria
11Rheumatology, Hospital of Bruneck, Bruneck, Italy
12Division of Rheumatology, Department of Internal Medicine, Istanbul University Cerrahpaşa Faculty of Medicine, Istanbul, Turkey
13Department of Internal Medicine, Rheumatology and Immunology, Medus Kliniken, Karl-Albrechts-Universität Tübingen, Kirchheim-Teck, Germany
14Hospital Saint-Louis, University Paris Diderot, Paris, France
15Ophthalmology, University Hospitals Birmingham, Birmingham, UK
16Neurometabolism, Institute of Metabolism and Systems Research, University of Nottingham, Nottingham, UK
17Rheumatology, Hospital de Santa Maria - CHUL, Lisbon Academic Medical Centre, Lisbon, Portugal
18Rheumatology Research Unit; Instituto de Medicina Molecular, Instituto de Medicina Molecular, Lisboa, Portugal
19Artesipedica S Maria Nuova, Reggio Emilia, Italy
20Stroke and Neurocritical Care, GLB Hospitals and Acute Stroke Centers, Chennai, India
21Division of Rheumatology and Clinical Immunology / Allergy, University Hospital (Inselspital), Bern, Switzerland
22Rheumatology, Peking Union Medical College Hospital, Beijing, China
23University of Iceland, Reykjavik, Iceland
24Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
25Medical Centre for Rheumatology Berlin-Charité, Berlin, Germany
26Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK
27Rheumatology, Hospital de Santa Maria - CHUL, Lisbon Academic Medical Centre, Lisbon, Portugal
28Hospital Saint Louis, University Paris Diderot, Paris, France
29Division of Rheumatology, Department of Internal Medicine, Istanbul University Cerrahpaşa Faculty of Medicine, Istanbul, Turkey
30Department of Internal Medicine, Rheumatology and Immunology, Medus Kliniken, Karl-Albrechts-Universität Tübingen, Kirchheim-Teck, Germany
31Hospital Saint-Louis, University Paris Diderot, Paris, France
32Ophthalmology, University Hospitals Birmingham, Birmingham, UK
33Neurometabolism, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
34Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK
35Rheumatology, Hospital de Santa Maria - CHUL, Lisbon Academic Medical Centre, Lisbon, Portugal
36Rheumatology Research Unit; Instituto de Medicina Molecular, Instituto de Medicina Molecular, Lisboa, Portugal
37Artesipedica S Maria Nuova, Reggio Emilia, Italy
38Stroke and Neurocritical Care, GLB Hospitals and Acute Stroke Centers, Chennai, India
39Rheumatology, Peking Union Medical College Hospital, Beijing, China
40University of Iceland, Reykjavik, Iceland
41Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
42Medical Centre for Rheumatology Berlin-Charité, Berlin, Germany
43Rheumatology and Clinical Immunology / Allergy, University Hospital (Inselspital), Bern, Switzerland
44Norwich Medical School, Bob Champion Research and Education Building, University of East Anglia, Norwich, UK
45Steyning, UK
46Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NORDMRs), University of Oxford, Oxford, UK

Correction notice
This article has been corrected since it published Online First. The third affiliations has been updated and the author’s names for Maria C Cid and Wolfgang Schmidt have been corrected.

Acknowledgements
The authors wish to thank the librarians Chiara Rebuffi, Gold Office and Scientific Documentation centre, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Helena Donato, Documentation Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, for advice and assistance during the SLR.

Contributors
AA and SM conducted the SLR. RL provided substantial methodological advice. BH drafted the first version of the manuscript and subsequent revisions. All authors were involved in the formulation and discussion of the recommendations, reviewed the manuscript and made extensive comments and changes to it. The final version of the manuscript was approved by all authors.

Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
EB received consultancy fees from Roche (payed to the University Medical Center Groningen). FB received grants from Horizon and Mundipharma and speaker fees and/or consultancies from Horizon, Mundipharma, Roche and Sanofi. HB received a grant and speaker fees from Roche. BD received consultancies and/or speaker fees from BMS, Chugai, GSK and Roche. CD received and grant from Celgene and speaker fees and/or consultancies from Abbvie, BMS, Lilly, MSD, Pfizer, Novartis, UCB, Roche and Sanofi. BH received speaker fees and/or consultancies from Abbvie, Boehringer, Chugai, Celgene, MSD, Pfizer, Novartis and Roche. SM received speaker fees and consultancies from Roche and Chugui. WS received a grant from Roche and speaker fees and consultancies from Chugui, GSK, Novartis, Roche and Sanofi. CT received a grant from BMS and speaker fees and/or consultancies from Abbvie, BMS, Pfizer and Roche. PV received a grant for conducting an RCT in GCA from Roche. All other authors have no competing interests.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

ORCID iDs
Bernhard Hellmich http://orcid.org/0000-0002-8014-1801
Christian Dejaco http://orcid.org/0000-0002-0173-0668
Gulen Hatemi http://orcid.org/0000-0002-1952-1135
Chetan Mukhiyar http://orcid.org/0000-0002-9771-6667

REFERENCES


Recommendation

Methods

The recommendations were drafted according to the 2014 update of the EULAR standardised operating procedures (SOPs) for the development of EULAR-endorsed recommendations and the updated version of the Appraisal of Guidelines for Research & Evaluation (AGREE II) instrument, where applicable. After approval by the EULAR Executive Committee, the Convenor (BH) and the methodologist (RL) assembled a task force including 24 members. The group consisted of 19 clinical experts (including rheumatologists, internists, immunologists, a neurologist, a neuro-ophthalmologist, and an epidemiologist), from 11 European countries, India and China, two fellows (AA, SM), one health professional and two patients affected by the diseases under study. Three members of the task force (SM, CP, CD) were EMEUNET members.

Based on results of a Delphi survey among the task force, we defined eight key research questions addressing the management and treatment of LVV. As the original systematic literature review (SLR) for the 2008 recommendations dated back 10 years ago with different methodology (focus, bias assessment etc.), it was decided to conduct two completely new SLRs without time limits, focusing on general management and treatment respectively (Table 1).

### Table S1. Topics for the Systematic Literature Search

<table>
<thead>
<tr>
<th>SLR 1: General Management</th>
<th>SLR 2: Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>- diagnosis: recognition, referral criteria, fast-track diagnosis, role of imaging for diagnosis, role of biopsy for diagnosis, interdisciplinary work-up, considerations for sub-types of disease such as cranial/ischaemic/large vessel, isolated aortitis, IgG4-related disease, LVV disease in other vasculitides</td>
<td>- drug therapy: dosing, length of therapy, outcome and treatment-related side effects for the following drugs: glucocorticoids, methotrexate and other non-biologic immunosuppressive agents, tocilizumab and other biologic agents;</td>
</tr>
<tr>
<td>- prognostic and therapeutic implications of disease phenotypes: cranial vs extra-cranial, isolated aortitis, other forms including IgG-4 related disease, imaging, other biomarkers, comorbidities and complications, disease damage versus activity</td>
<td>- specific treatment of organ complications: loss of vision and stroke), relapsing, refractory, glucocorticoid-dependent disease</td>
</tr>
<tr>
<td>- long-term follow-up of patients: clinical assessments and frequency, imaging, patient-reported outcomes, physical therapies and management of complications</td>
<td>- revascularisation procedures: indications for referral, management of aneurysms and/or vessel stenosis</td>
</tr>
<tr>
<td>- patient education and other aspects of patients-centered care</td>
<td>- adjunctive therapies and prophylaxis: aspirin, cardiovascular and cerebrovascular disease, infections, vaccination, osteoporosis</td>
</tr>
</tbody>
</table>

The research strategy was framed according to the Population, Intervention, Comparator, Outcome (PICO) format. Both SLRs included the same population terms (including GCA, TAK and other forms of LVV), focusing on different interventions and outcomes. Given the wide area of
topics covered by each SLR, a comparator did not apply to our search strategies and was excluded. The two fellows (SM and AA) performed the SLR with the guidance of two experienced librarians and the methodologist (RL) by exploiting the following databases: MEDLINE, EMBASE and Cochrane CENTRAL. Evidence was gathered from inception of each database until the 31st of December 2017. Eligible studies were all full research articles of any study design, without language restrictions, but excluding single-case-reports and reviews. Summary of findings (SoF) tables were created. Following the 2014 EULAR standard operating procedures and 2017 additional guidance document for the development/update of EULAR recommendations, each article was assigned a level of evidence (LoE) according to the 2009 standards of the Oxford Centre for Evidence-Based Medicine and was systematically assessed for bias. The results of the two SLRs and a detailed outline of the search strategy, methods and obtained evidence are published separately (NOTE TO THE EDITOR: references to be added when the accompanying manuscripts are finished).

During a face-to-face meeting, the SoF-tables derived from the SLRs were presented and formed the basis for the generation of the recommendations. After discussion, task force members independently voted on each recommendation. Only the recommendations (here presented in italic font) were formally voted on during the face-to-face meeting, but not the subsequent paragraphs. Agreement of at least 75% of the task force members was required in the first ballot, which was achieved for all recommendations. After the meeting, participants were asked via email to anonymously report their level of agreement on each recommendation and on the overarching principles on a scale of 0-10 (10 meaning full agreement). A research agenda was formulated from the gaps in the evidence and any controversial issues. The final manuscript was approved by the EULAR Executive Committee.
## Supplementary file 2

### Table S2. EULAR consensus definitions for disease activity states in GCA and other types of LVV compared to definitions used in the GiACTA trial

<table>
<thead>
<tr>
<th>Activity State</th>
<th>EULAR Consensus Definition</th>
<th>Definition GiACTA trial</th>
</tr>
</thead>
</table>
| **Active disease** | 1. The presence of typical signs or symptoms of active LVV (Table 4)  
AND  
2. at least one of the following:  
a) current activity on imaging or biopsy  
b) ischaemic complications attributed to LVV  
c) persistently elevated inflammatory markers (after other causes have been excluded) | 1. at least one of the following within 6 weeks of baseline visit  
a) unequivocal cranial symptoms of GCA (new onset localized headache, scalp or temporal artery tenderness, ischemia-related vision loss, or otherwise unexplained mouth or jaw pain upon mastication)  
b) unequivocal symptoms of polymyalgia rheumatica (PMR), defined as shoulder and/or hip girdle pain associated with inflammatory stiffness  
c) other features judged by the clinician investigator to be consistent with GCA or PMR flares (i.e., new or worsened extremity claudication, fever of unknown origin)  
2. and ESR ≥30 mm/hr or CRP ≥1 mg/dL |
| **Flare** | We do not recommend use of this term recurrence of symptoms attributable to active GCA, with or without elevation of ESR and/or CRP |
| **Relapse** | We recommend use of the terms Major Relapse or Minor Relapse as defined below diagnosis of GCA >6 weeks of baseline visit and active disease within 6 weeks of baseline visit |
| **Major relapse** | Recurrence of active disease with either of the following:  
a) Clinical features of ischaemia* (including jaw claudication, visual symptoms, visual loss attributable to GCA, scalp necrosis, stroke, limb claudication)  
b) Evidence of active aortic inflammation resulting in progressive aortic or large vessel dilatation, stenosis or dissection | - |
| **Minor relapse** | Recurrence of active disease, not fulfilling the criteria for a major relapse | - |
| **Refractory** | Inability to induce remission (with evidence of reactivation of disease, as defined above in “Active disease”) despite the use of standard care therapy | Diagnosis of GCA >6 weeks of baseline visit and active disease within 6 weeks of baseline visit |
| **Remission** | Absence of all clinical signs and symptoms attributable to active LVV and normalization of ESR and CRP; in addition for patients with extracranial disease, there should be no evidence of progressive vessel narrowing or dilatation | Absence of all symptoms attributable to active GCA and normalization of ESR (<30 mm/hr) and CRP (<1 mg/dL) |
| **Sustained remission** | 1 Remission for at least 6 months AND 2. achievement of the individual target GC dose | 1. Absence of flare following remission by week 12 after randomization 2. And completion of the assigned prednisone taper 3. And not having required escape therapy at any time by week 52. |
| **Glucocorticoid-free remission** | Sustained remission AND Discontinued GC therapy (but could still be receiving other immunosuppressive therapy) | No definition was provided |

*Some symptoms listed are typical only for GCA and may require further diagnostic work-up if present in other types of LVV*